Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.95 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)960.50K
Market Cap
$14.12B
Enterprise Value$11.08B
Total Cash (Recent Filing)$307.35M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)38.2
Beta0.46
Next Earnings
Feb 11, 2025EPS Estimate
1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding101,246,910
10 Day Avg. Volume950,318
30 Day Avg. Volume960,504
Standard Deviation0.08
R-Squared0.04
Alpha0.00350
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.44
Price to Cash Flow (P/CF)22.80
P/FCF Ratio24.10
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda19.90
Forecast
1Y Price Target
$166.88Price Target Upside17.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessCrinecerfont's Phase 3 results support broad application, indicating strong clinical success.
Market PotentialThe market for CAH is seen as underappreciated over the longer term, indicating significant growth potential for NBIX.
Product ApprovalThe FDA approved Crenessity for classic congenital adrenal hyperplasia for adult and pediatric patients, which was modestly earlier than expected.
Bears Say
Clinical TrialsRecent clinical trial struggles, specifically in epilepsy, make analysts interested in these assets, but unlikely to ascribe much value.
Launch ChallengesA slow launch of Crenessity is anticipated due to challenges such as limited broad commercial access and a complicated dosing regimen.
Market AcceptanceCrenessity's annual list price is significantly higher than market expectations, which could impact affordability and market acceptance.
---
Ownership Overview
1.04% Insiders
22.90% Mutual Funds
0.28% Other Institutional Investors
48.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $110.95 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $14.12B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Feb 11, 2025 which is in 24 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Oct 30, 2024. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.505 by -$0.265.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.62.
How many shares outstanding does Neurocrine have?
Neurocrine has 101,246,910 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.24 in its last earnings report, missing expectations of $1.505. Following the earnings report the stock price went up 7.006%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$166.88 (17.59% Upside)
$166.88 (17.59% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 66.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.01%
12-Months-Change
Fundamentals
Return on Equity
14.19%
Trailing 12-Months
Asset Growth
24.11%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong sales figures for INGREZZA and significant progress in pipeline development. While some challenges were noted, particularly in terms of competition and program discontinuations, the strategic initiatives like the share repurchase plan and sales force expansion reflect confidence in future growth.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$166.88
▲(17.59% Upside)
Technical Analysis
SAGE Therapeutics
―
ACADIA Pharmaceuticals
―
Alkermes
―
Vertex Pharmaceuticals
―
Incyte
―
Xencor
―
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
22/27 ratings generated profit
1 Year Average Return
+12.64%
assigned a buy rating 5 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 81.48% of your transactions generating a profit, with an average return of +12.64% per trade.
---